P Wongwerawattanakoon

Publications (5)12.98 Total impact

• Article: Safety and efficacy of recombinant activated factor VII for long-term secondary prophylaxis in a haemophilia boy with high-titre inhibitors.

  A Chuansumrit, N Sirachainan, M Panuwannakorn, P Wongwerawattanakoon, P Kadegasem, W Choeyprasert, W Sasanakul
  Haemophilia 05/2013; 19(3):e182-3. · 2.60 Impact Factor
• Article: Simple and accurate bedside diagnostic kit for determining haemophilia A and B: a revised version.

  W Sasanakul, P Kadegasem, W Chaiyaratana, P Wongwerawattanakoon, N Sirachainan, A Chuansumrit
  Haemophilia 10/2012; · 2.60 Impact Factor
• Article: Accurate bedside diagnostic kit for determining haemophilia A and B.

  A Chuansumrit, B Pongtanakul, P Kadegasem, W Sasanakul, S Chotsupakarn, P Kitpoka, P Wongwerawattanakoon, S Bejrachandra
  Haemophilia 09/2008; 15(1):361-4. · 2.60 Impact Factor
• Article: Efficacy of different doses of recombinant activated factor VII in the treatment of haemophilia children with inhibitor.

  A Chuansumrit, N Sirachainan, S Pakakasama, A Suebsangad, S Chotsuppakarn, P Wongwerawattanakoon
  Haemophilia 07/2008; 14(5):1143-4. · 2.60 Impact Factor
• Source

  Available from: mahidol.ac.th

  Article: Rituximab as an adjuvant therapy to immune tolerance in a haemophilia A boy with high inhibitor titre.

  A Chuansumrit, S Husapadol, P Wongwerawattanakoon, S Hongeng, N Sirachainan, S Pakakasama
  [show abstract] [hide abstract]
  ABSTRACT: We report a haemophilia A boy with high inhibitor titre (170 BU) who experienced five life-threatening bleeding episodes during a one-year period from 9 to 21 months. At the age of 22 months, he received rituximab (375 mg m(-2) per dose) at one- and three-week intervals, three courses each and alternative daily treatment with factor VIII concentrate at doses of 100 units kg(-1) for 24 weeks and 50 units kg(-1) for the following 28 weeks. Although the pretreatment inhibitor level of 4.5 BU showed an anamnestic response reaching the maximum level of 200 BU at the 9th week of treatment, it gradually declined to 30 BU at the 22nd week and was constantly maintained at 25-30 BU for the following 30 weeks. Only three bleeding episodes of two haematomas and one haemarthrosis were found during the one-year treatment period. No opportunistic infection occured during this period.
  Haemophilia 02/2007; 13(1):108-10. · 2.60 Impact Factor